Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03957096 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-CD47M in Patients With Solid Tumors
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03957096 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 16 participants.
The verdict
NCT03957096, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts. Part A of the study will find out how much SGN-CD47M should be given for treatment and how often. Part B of the study will use the dose found in Part A and look at how safe and effective the treatment is.
Interventions
- DRUG SGN-CD47M
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-07-17 |
| Est. Completion | 2020-09-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03957096
The ClinicalTrials.gov registry entry for NCT03957096 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-CD47M is the first listed.
NCT03957096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03957096 about?
NCT03957096 is a clinical study titled "A Safety Study of SGN-CD47M in Patients With Solid Tumors". This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts. Part A of the study will find out how much SGN-CD47M should be given for treatment and how often. Pa...
What is the current status of trial NCT03957096?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-07-17. Estimated completion is 2020-09-14.
What interventions are being tested in trial NCT03957096?
The interventions under investigation include: SGN-CD47M (DRUG).
Who is sponsoring clinical trial NCT03957096?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.